Fengyuan Pharmaceutical (000153.SZ) subsidiary receives approval notice for the listing application of the chemical raw material drug Fumaric Acid Vonoprazan.

Fengyuan Pharmaceutical (000153.SZ) announced that recently, its wholly-owned subsidiary, Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd., received the 'Approval Notice for Chemical Raw Material Drug Marketing Application' issued by the National Medical Products Administration for Vonoprazan Fumarate. Vonoprazan Fumarate is a potassium-competitive acid blocker (P-CAB) that can inhibit gastric acid production and prevent damage to the upper gastrointestinal mucosa. It is primarily used in the treatment of gastroesophageal reflux disease and Helicobacter pylori infection.

Zhitong FinanceMay 12 17:28

Express News | Fengyuan Pharmaceutical: Obtains Drug Registration Certificate for Compound Polyethylene Glycol Electrolyte Powder

BreakingsMay 7 16:30

Fengyuan Pharmaceutical: First Quarter Report for 2026

SZSIApr 29 00:00 · Announcements

Fengyuan Pharmaceutical: 2025 Annual Report

SZSIApr 29 00:00 · Announcements

Fengyuan Pharmaceutical: Summary of the 2025 Annual Report

SZSIApr 29 00:00 · Announcements

Stocks in the A-share market showed unusual movements as a collective rise occurred among flu-related concept stocks, amid reports that China's influenza positivity rate has increased for three consecutive weeks.

Gelonghui, April 15 | The A-share market's flu concept stocks collectively rose. By the close of trading, BrightGene Bio-Medical Technology surged by 20%, Innovax Biotech increased by over 14%, Conba Pharmaceutical, Peking University Medicine, Hisun Pharmaceuticals, Double-Crane Pharmaceuticals, and Harbin Pharmaceutical Group all surged by 10%, Corally Medical rose by over 7%, Jiande Zhixin and Fengyuan Pharmaceutical increased by over 6%, Huaren Pharmaceuticals grew by over 5%, Kangzhi Pharmaceutical, Hotgen Biotech, Yipinhong Pharmaceutical, and Kelun Pharmaceuticals rose by over 4%. In terms of news, according to recent data released by the Chinese Center for Disease Control and Prevention (CDC) on national sentinel surveillance of acute respiratory infectious diseases, the positive rate of national influenza virus detection has risen for three consecutive weeks. The latest monitoring data shows: 20

Gelonghui FinanceApr 15 15:05